Investment
Features
FeesSafety
Academy
More
Pluang+

High Templar launches tender offer to buy up to 39M ADS at $2.80-$3.20 each, under $300M buyback program

Company Fundamentals
26 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

High Templar Tech Limited has initiated a modified Dutch auction tender offer to repurchase up to 39 million American Depositary Shares (ADS) at prices between $2.80 and $3.20 per share. This offer is part of the company's $300 million share repurchase program announced in March 2024. The tender offer will expire on June 24, 2026, unless extended, and allows shareholders to specify the number of shares and price within the range they are willing to sell. The company may increase the number of shares it seeks to buy by up to 2% if demand exceeds 39 million ADS. This buyback aims to return value to shareholders and may continue via other methods after the tender offer period.

More News

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...

Others
Neutral
1 hour ago
ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...

Others
Bullish
2 hours ago
Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...

Company Fundamentals
Bullish
3 hours ago
Foresight Financial's Q2 net income rises 47% on margin growth and cost cuts

Foresight Financial's Q2 net income rises 47% on margin growth and cost cuts

Foresight Financial Group reported a 47% increase in net income to $4.38 million for Q2 2026, driven by higher net interest income, margin expansion, and lower credit costs. Earnings per share rose to $1.20, with improved efficiency and asset quality...

Company Fundamentals
Bullish
4 hours ago
Klarna's growth driven by strong financing, low-cost funding, and expanding customer base despite market volatility risks.

Klarna's growth driven by strong financing, low-cost funding, and expanding customer base despite market volatility risks.

Klarna benefits from maturing financing cohorts, low-cost deposit funding, and prudent risk management, leading to increased transaction margins and net interest income. This supports their growth strategy, reflected in accelerating gross merchandise...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App